International journal of women's health · 2026
Predictive Value of Serum Pentraxin 3 and Galectin-3 in Early Pregnancy for Gestational Diabetes Mellitus in Chinese Women.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Su Qing, Yang Ji, Yang Jin, Zhang Hui, Fan Yanfen
Аннотация
OBJECTIVE: Gestational diabetes mellitus (GDM) is a common metabolic complication during pregnancy. Early identification of high-risk women is critical for reducing maternal and fetal complications. This study aimed to explore the predictive value of serum pentraxin 3 (PTX3) and galectin-3 in early pregnancy for GDM among Chinese women.
METHODS: This retrospective case-control study recruited pregnant women with a first prenatal visit before 14 weeks of gestation. Serum samples were collected at enrollment. All participants were followed up to 24-28 weeks, and GDM was confirmed via standard 75 g oral glucose tolerance test (OGTT). Correlation analysis, ROC curve and binary logistic regression were used to evaluate predictive efficacy. A total of 120 eligible women were divided into the GDM group (n=60) and healthy control group (n=60).
RESULTS: FBG, FINS, PTX3 and galectin-3 levels were markedly elevated in GDM group (P < 0.05). Both biomarkers were positively correlated with glucose and insulin indexes (P < 0.05). The AUC values of PTX3 and galectin-3 were 0.821 and 0.662 respectively. The combined detection yielded an AUC of 0.877, with a sensitivity of 86.5% and a specificity of 92.3%. PTX3 and galectin-3 were verified as independent risk factors of GDM.
CONCLUSION: First-trimester PTX3 and galectin-3 can serve as effective biomarkers for GDM prediction. Combined detection improves diagnostic efficiency and facilitates early screening for high-risk populations. Due to the single-center design and 1:1 grouping inconsistent with actual GDM prevalence, further prospective multicenter studies are required to validate our findings.
METHODS: This retrospective case-control study recruited pregnant women with a first prenatal visit before 14 weeks of gestation. Serum samples were collected at enrollment. All participants were followed up to 24-28 weeks, and GDM was confirmed via standard 75 g oral glucose tolerance test (OGTT). Correlation analysis, ROC curve and binary logistic regression were used to evaluate predictive efficacy. A total of 120 eligible women were divided into the GDM group (n=60) and healthy control group (n=60).
RESULTS: FBG, FINS, PTX3 and galectin-3 levels were markedly elevated in GDM group (P < 0.05). Both biomarkers were positively correlated with glucose and insulin indexes (P < 0.05). The AUC values of PTX3 and galectin-3 were 0.821 and 0.662 respectively. The combined detection yielded an AUC of 0.877, with a sensitivity of 86.5% and a specificity of 92.3%. PTX3 and galectin-3 were verified as independent risk factors of GDM.
CONCLUSION: First-trimester PTX3 and galectin-3 can serve as effective biomarkers for GDM prediction. Combined detection improves diagnostic efficiency and facilitates early screening for high-risk populations. Due to the single-center design and 1:1 grouping inconsistent with actual GDM prevalence, further prospective multicenter studies are required to validate our findings.